Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

Autor: Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C.C. Fong, Tilman Todenhöfer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono

Publikováno v: Scientia

Metastatic castration-resistant prostate cancer; Olaparib; Pembrolizumab Cáncer de próstata metastásico resistente a la castración; Olaparib; Pembrolizumab Càncer de pròstata metastàtic resistent a la castració; Olaparib; Pembrolizumab Backgr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca3f75fdc923eda1b2b738df1dc19c8
https://doi.org/10.1016/j.eururo.2022.08.005

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

Autor: Gillessen S; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: silke.gillessen@eoc.ch., Turco F; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland., Davis ID; Monash University, Melbourne, Australia; Eastern Health, Melbourne, Australia., Efstathiou JA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Fizazi K; Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., James ND; Institute of Cancer Research, London, UK., Shore N; Carolina Urologic Research Center and GenesisCare, Myrtle Beach, SC, USA., Small E; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA., Smith M; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia., Tombal B; Division of Urology, Clinique Universitaire St. Luc, Brussels, Belgium., Zilli T; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Antonarakis ES; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA., Aparicio A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Armstrong AJ; Center for Prostate and Urologic Cancer, Duke Cancer Institute, Duke University, Durham, NC, USA., Bastos DA; Hospital Sirio-Libanês, São Paulo, Brazil., Attard G; UCL Cancer Institute, University College London, London, UK., Axcrona K; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Urology, Akershus University Hospital, Lørenskog, Norway., Ayadi M; Salah Azaiz Institute, Medical School of Tunis, Tunis, Tunisia., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Bjartell A; Department of Urology, Skåne University Hospital, Malmö, Sweden., Blanchard P; Department of Radiation Oncology, Oncostat U1018 INSERM, Université Paris-Saclay, Gustave-Roussy, Villejuif, France., Bourlon MT; Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Briganti A; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy., Bulbul M; Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon., Buttigliero C; Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Italy., Caffo O; Medical Oncology Department, Santa Chiara Hospital, APSS, Trento, Italy., Castellano D; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Castro E; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Cheng HH; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA; Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA USA., Chi KN; BC Cancer and University of British Columbia, Vancouver, Canada., Clarke CS; Research Department of Primary Care and Population Health, University College London, London, UK., Clarke N; The Christie and Salford Royal Hospitals, Manchester, UK., de Bono JS; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK., De Santis M; Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria., Duran I; Medical Oncology Department, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain., Efstathiou E; Houston Methodist Cancer Center, Houston, TX, USA., Ekeke ON; Urology Division, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria., El Nahas TIH; Kasr Al Ainy Hospital, Cairo University, Giza, Egypt., Emmett L; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, UNSW Sydney, Sydney, Australia., Fanti S; Department of Nuclear Medicine, IRCCS AOU Bologna, Bologna, Italy., Fatiregun OA; Lagos State University Teaching Hospital, Ikeja, Nigeria., Feng FY; University of California-San Francisco, San Francisco, CA, USA., Fong PCC; Auckland City Hospital and University of Auckland, Auckland, New Zealand., Fonteyne V; Ghent University Hospital, Ghent, Belgium., Fossati N; Department of Surgery (Urology Service), Ente Ospedaliero Cantonale, Università della Svizzera Italiana Lugano, Switzerland., George DJ; Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA., Gleave ME; Department of Urologic Sciences, University of British Columbia, Vancouver, Canada., Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France., Halabi S; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA., Heinrich D; Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway., Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany., Hofman MS; Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Hope TA; Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, USA., Horvath LG; Chris O'Brien Lifehouse, University of Sydney, Sydney, Australia., Hussain MHA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Jereczek-Fossa BA; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Department of Radiation Oncology, European Institute of Oncology IRCCS, Milan, Italy., Jones RJ; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia., Kanesvaran R; Division of Medical Oncology, National Cancer Centre, Singapore., Keizman D; Genitourinary Unit, Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel., Khauli RB; Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon; Division of Urology, Carle-Illinois College of Medicine, Urbana, IL, USA., Kramer G; Department of Urology, Medical University of Vienna, Vienna, Austria., Loeb S; Department of Urology and Population Health, New York University Langone Health, New York, NY, USA; Department of Surgery/Urology, Manhattan Veterans Affairs, New York, NY, USA., Mahal BA; Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA., Maluf FC; Beneficiência Portuguesa de São Paulo, São Paulo, Brazil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, Brazil., Mateo J; Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Matheson D; Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK., Matikainen MP; Department of Urology, Helsinki University Hospital, Helsinki, Finland., McDermott R; Department of Medical Oncology, St. Vincent's University Hospital and Cancer Trials, Dublin, Ireland., McKay RR; University of California-San Diego, Palo Alto, CA, USA., Mehra N; Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands., Merseburger AS; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany., Morgans AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mrabti H; Institut National d'Oncologie, Mohamed V University, Rabat, Morocco., Mukherji D; Clemenceau Medical Center, Dubai, United Arab Emirates; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon., Murphy DG; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia., Murthy V; Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India., Mutambirwa SBA; Department of Urology, Sefako Makgatho Health Science University, Dr. George Mukhari Academic Hospital, Medunsa, South Africa., Nguyen PL; Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Oh WK; Division of Hematology and Medical Oncology, Tisch Cancer Institute at Mount Sinai, New York, NY, USA., Ost P; Department of Radiation Oncology, Iridium Network, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium., O'Sullivan JM; Patrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK., Padhani AR; Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK., Parker C; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK., Poon DMC; Hong Kong Sanatorium and Hospital, Chinese University of Hong Kong, Hong Kong, China., Pritchard CC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Rabah DM; Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Urology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia., Rathkopf D; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reiter RE; University of California-Los Angeles, Los Angeles, CA, USA., Renard-Penna R; Department of Imagery, GRC 5 Predictive Onco-Uro, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France., Ryan CJ; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA., Saad F; Centre Hospitalier de Université de Montréal, Montreal, Canada., Sade JP; Instituto Alexander Fleming, Buenos Aires, Argentina., Sandhu S; Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Sartor OA; Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA., Schaeffer E; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Scher HI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sharifi N; Desai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Skoneczna IA; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Soule HR; Prostate Cancer Foundation, Santa Monica, CA, USA., Spratt DE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA., Srinivas S; Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA., Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA., Suzuki H; Department of Urology, Toho University Sakura Medical Center, Sakura, Japan., Taplin ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thellenberg-Karlsson C; Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden., Tilki D; Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg Eppendorf, Hamburg, Germany., Türkeri LN; Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey., Uemura H; Yokohama City University Medical Center, Yokohama, Japan., Ürün Y; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey., Vale CL; MRC Clinical Trials Unit, University College London, London, UK., Vapiwala N; Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Walz J; Institut Paoli-Calmettes Cancer Center, Marseille, France., Yamoah K; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Yu EY; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA; Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA USA., Zapatero A; University Hospital La Princesa, Health Research Institute, Madrid, Spain., Omlin A; Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.

Publikováno v: European urology [Eur Urol] 2024 Oct 10. Date of Electronic Publication: 2024 Oct 10.

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.

Autor: Fizazi K; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. karim.fizazi@gustaveroussy.fr., Azad AA; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Matsubara N; National Cancer Center Hospital East, Chiba, Japan., Carles J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Fay AP; PUCRS School of Medicine, Porto Alegre, Brazil., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Joung JY; National Cancer Center, Goyang, Republic of Korea., Fong PCC; Auckland City Hospital, Auckland, New Zealand.; University of Auckland, Auckland, New Zealand., Voog E; Clinique Victor Hugo Centre Jean Bernard, Le Mans, France., Jones RJ; School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Dunshee C; Arizona Urology Specialists, Tucson, AZ, USA., Zschäbitz S; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany., Oldenburg J; Akershus University Hospital (Ahus), Lørenskog, Norway., Ye D; Fudan University Shanghai Cancer Center, Shanghai, China., Lin X; Pfizer Inc., La Jolla, CA, USA., Healy CG; Pfizer Inc., Collegeville, PA, USA., Di Santo N; Pfizer Inc., Durham, NC, USA., Laird AD; Pfizer Inc., La Jolla, CA, USA., Zohren F; Pfizer Inc., New York, NY, USA., Agarwal N; Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA. neeraj.agarwal@hci.utah.edu.

Publikováno v: Nature medicine [Nat Med] 2024 May; Vol. 30 (5), pp. 1505.

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.

Autor: Fizazi K; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. karim.fizazi@gustaveroussy.fr., Azad AA; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Matsubara N; National Cancer Center Hospital East, Chiba, Japan., Carles J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Fay AP; PUCRS School of Medicine, Porto Alegre, Brazil., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Joung JY; National Cancer Center, Goyang, Republic of Korea., Fong PCC; Auckland City Hospital, Auckland, New Zealand.; University of Auckland, Auckland, New Zealand., Voog E; Clinique Victor Hugo Centre Jean Bernard, Le Mans, France., Jones RJ; School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Dunshee C; Arizona Urology Specialists, Tucson, AZ, USA., Zschäbitz S; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany., Oldenburg J; Akershus University Hospital (Ahus), Lørenskog, Norway., Ye D; Fudan University Shanghai Cancer Center, Shanghai, China., Lin X; Pfizer Inc., La Jolla, CA, USA., Healy CG; Pfizer Inc., Collegeville, PA, USA., Di Santo N; Pfizer Inc., Durham, NC, USA., Laird AD; Pfizer Inc., La Jolla, CA, USA., Zohren F; Pfizer Inc., New York, NY, USA., Agarwal N; Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA. neeraj.agarwal@hci.utah.edu.

Publikováno v: Nature medicine [Nat Med] 2024 Jan; Vol. 30 (1), pp. 257-264. Date of Electronic Publication: 2023 Dec 04.

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].

Autor: Yu EY; University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: evanyu@u.washington.edu., Piulats JM; Catalan Institute of Oncology, Barcelona, Spain., Gravis G; Institut Paoli Calmettes, Marseille, France., Fong PCC; Auckland City Hospital, Auckland, New Zealand; University of Auckland, Auckland, New Zealand., Todenhöfer T; Studienpraxis Urologie, Nürtingen, Germany., Laguerre B; Centre Eugène Marquis, Rennes, France., Arranz JA; General University Hospital Gregorio Marañón, Madrid, Spain., Oudard S; Hôpital Européen Georges Pompidou, University of Paris, Paris, France., Massard C; Gustave Roussy, Cancer Campus, Villejuif, France; Paris-Saclay University, Villejuif, France., Heinzelbecker J; Saarland University Medical Center, Homburg, Germany; Faculty of Medicine, Saarland University, Homburg, Germany., Nordquist LT; GU Research Network-Urology Cancer Center, Omaha, NE, USA., Carles J; Vall d'Hebron Institute of Oncology, Vall d'Hebron, Barcelona, Spain., Kolinsky MP; Cross Cancer Institute and University of Alberta, Edmonton, AB, Canada., Augustin M; Paracelsus Medical University, Nuremberg, Germany., Gurney H; Macquarie University, Sydney, Australia., Tafreshi A; University of Wollongong, Wollongong, NSW, Australia., Li XT; Merck & Co., Inc., Rahway, NJ, USA., Qiu P; Merck & Co., Inc., Rahway, NJ, USA., Poehlein CH; Merck & Co., Inc., Rahway, NJ, USA., Schloss C; Merck & Co., Inc., Rahway, NJ, USA., de Bono JS; The Institute of Cancer Research and the Royal Marsden, London, UK.

Publikováno v: European urology [Eur Urol] 2023 Mar; Vol. 83 (3), pp. e87. Date of Electronic Publication: 2022 Dec 15.